Literature DB >> 12613778

Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis.

Hyeon Sook Kim1, Ji Hye Hwang, Soon Tak Jeong, Yong Taek Lee, Peter K W Lee, Yeon-Lim Suh, Jong Sup Shim.   

Abstract

The purpose of this study was to evaluate the effects of botulinum toxin A (BTX-A, Botox) dilution volume and post-injection exercise with electrical stimulation on muscle paralysis. We injected 10 units of BTX-A diluted with 0.1 ml (B1, n=8) or 0.5 ml (B5, n=8) normal saline into both gastrocnemius muscles of 16 New Zealand white rabbits; two controls received no BTX-A. After BTX-A injection, all rabbits received calf muscle stretching exercise and electrical stimulation for 2 hours on the left leg. The compound muscle action potential (CMAP) decrease was most pronounced at 1 week and progressive recovery was observed (i.e. recovery from paralysis, increase of CMAP). There was a significant decrease of CMAP amplitudes in the B5 group compared with the B1 group at week 1 and week 4 (p<0.001). Left limbs with stretching exercise and electrical stimulation showed lower CMAP amplitudes compared with control right limbs of all rabbits. To maximize the muscle paralysis effect of BTX-A, increasing dilution volume and performing post-injection stretching exercise with electrical stimulation may be a promising strategy for increasing the beneficial effect of BTX-A treatment. Future studies are needed to investigate the clinical application of this finding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12613778     DOI: 10.1017/s0012162203000380

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  16 in total

Review 1.  Botulinum toxin for cerebral palsy; where are we now?

Authors:  R E Morton; J Hankinson; J Nicholson
Journal:  Arch Dis Child       Date:  2004-12       Impact factor: 3.791

Review 2.  Neurophysiological effects of botulinum toxin type A.

Authors:  G Abbruzzese; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  Hypertonia in children: how and when to treat.

Authors:  Terence D Sanger
Journal:  Curr Treat Options Neurol       Date:  2005-11       Impact factor: 3.598

4.  Is electrical stimulation beneficial for improving the paralytic effect of botulinum toxin type A in children with spastic diplegic cerebral palsy?

Authors:  Dong-wook Rha; Eun Joo Yang; Ho Ik Chung; Hyoung Bin Kim; Chang-il Park; Eun Sook Park
Journal:  Yonsei Med J       Date:  2008-08-30       Impact factor: 2.759

5.  The Use of Botulinum Toxin for Treatment of Spasticity.

Authors:  Sheng Li; Gerard E Francisco
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.

Authors:  Christopher P Smith; David A Gangitano; Alvaro Munoz; Nilson A Salas; Timothy B Boone; K Roger Aoki; Joseph Francis; George T Somogyi
Journal:  Neurochem Int       Date:  2007-11-26       Impact factor: 3.921

7.  High-frequency, low-magnitude vibration does not prevent bone loss resulting from muscle disuse in mice following botulinum toxin injection.

Authors:  Sarah L Manske; Craig A Good; Ronald F Zernicke; Steven K Boyd
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

Review 8.  Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: a literature review.

Authors:  Eun Sook Park; Dong-Wook Rha
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

9.  Exploring strategies to prevent post-lobectomy space: transient diaphragmatic paralysis using Botulinum toxin type A (BTX-A).

Authors:  Seyda Ors Kaya; Habip Atalay; Hakan Riza Erbay; Ali Vefa Ozcan; Ibrahim Goksin; Burhan Kabay; Koray Tekin
Journal:  Int Semin Surg Oncol       Date:  2005-10-19

10.  Effect of the refrigerator storage time on the potency of botox for human extensor digitorum brevis muscle paralysis.

Authors:  Mee Young Park; Ki Young Ahn
Journal:  J Clin Neurol       Date:  2013-07-01       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.